Chronic progressive multiple sclerosis

This study is testing whether a subcutaneous (under the skin) injection of ocrelizumab works as well as the standard intravenous (IV) infusion for people with relapsing or primary progressive multiple sclerosis. The trial will compare how the drug is absorbed, its safety, and its…

This study followed 134 adults in Italy with active secondary progressive multiple sclerosis who were prescribed siponimod (Mayzent) as part of their routine care. Over 36 months, researchers measured how many patients experienced a confirmed worsening of disability or cognitive …

This study tested a treatment called extracorporeal photopheresis (ECP) in 15 people with multiple sclerosis. ECP is a procedure that filters a person's blood, treats it with light, and returns it to the body. The goal was to see if it is safe and if it can improve walking, hand …

This early-stage trial tested a new cell therapy called DUOC-01, made from donated umbilical cord blood, in 20 adults with primary progressive multiple sclerosis (PPMS). The cells were injected into the spinal fluid to see if it was safe. Researchers also looked for early signs o…

This Phase 3 trial tested whether the oral drug tolebrutinib can delay disability progression in people with primary progressive multiple sclerosis (PPMS). 767 adults with PPMS received either tolebrutinib or a placebo. The study measured time to confirmed disability worsening ov…

This study looked at how ocrelizumab, a standard MS medication, changes brain inflammation in 22 people with multiple sclerosis. Researchers used special PET and MRI scans to measure inflammation before and after one year of treatment. The goal was to see if the drug reduces harm…

This phase 2 trial tested a liquid suspension of gold nanocrystals, called CNM-Au8, in 33 people with relapsing multiple sclerosis. The goal was to see if the treatment could improve energy metabolism in brain cells, measured by a special MRI scan. Participants took the drug by m…

This pilot study tests whether a special MRI contrast agent called ferumoxytol can highlight areas of active inflammation in the brains of people with secondary progressive multiple sclerosis (SPMS). The goal is to see if this imaging method can distinguish chronic-active lesions…

This trial tests whether N-acetyl cysteine (NAC), an antioxidant supplement, can reduce fatigue in people with progressive multiple sclerosis. Participants take NAC or a placebo three times daily for four weeks, and researchers measure changes in fatigue scores and brain chemistr…

This trial investigates whether a non-invasive technique called transcranial direct current stimulation (tDCS) can help with fatigue, depression, anxiety, and cognitive problems in people with multiple sclerosis (MS). tDCS uses a weak electrical current applied to the scalp to ge…

This study tested whether a 12-week exercise program using coordinated arm movements could improve brain function and movement in people with progressive multiple sclerosis (MS). Five adults with progressive MS did the exercises three times a week. Researchers measured brain acti…

This study follows 66 people with primary progressive multiple sclerosis (PPMS) and healthy volunteers for two years to understand how thinking and memory change over time. Participants take cognitive tests and undergo MRI scans to see how brain tissue damage relates to mental de…

This study used advanced MRI scans to look at energy use in the brains of 40 people with multiple sclerosis and 15 healthy volunteers. The goal was to see if energy problems in brain cells can predict nerve damage over two years. Researchers hope this will help understand how MS …

This study used a special eye camera (adaptive optics) to look at blood vessel inflammation in the retina of 50 people with multiple sclerosis (MS) and healthy volunteers. The goal was to see if this inflammation differs between MS types and could serve as an early marker of dise…

This study looked at 46 people with progressive multiple sclerosis who have more weakness on one side of their body. Researchers used MRI scans to see how damage in the brain and spinal cord relates to muscle strength in each limb. The goal was to better understand what causes ph…

This study analyzed MRI scans from 732 people with primary-progressive multiple sclerosis who took part in the ORATORIO trial. Researchers wanted to see if ocrelizumab changes a part of the brain called the choroid plexus, which may be involved in inflammation. The study was obse…

This completed study measured two proteins in the blood—neurofilament light chain and GFAP—that can signal nerve damage. Researchers compared 15 people with atypical MS, 30 with typical MS, and 15 healthy controls to see if these markers differ. The goal was to better understand …

This study looked back at medical records of 606 people with secondary progressive multiple sclerosis (SPMS) in Russia who were taking siponimod. Researchers wanted to understand patient characteristics and how the drug was used in everyday practice. The study collected data from…